AstraZeneca sells hypertension medicines to Atnahs Pharma

AstraZeneca has divested global commercial rights to a total of five hypertension drugs to Atnahs Pharma for a consideration of $350m.

The divested medicines comprise Inderal (propranolol), Tenormin (atenolol), Tenoretic (atenolol and chlorthalidone combination), Zestril (lisinopril) and Zestoretic (lisinopril and hydrochlorothiazide combination).

Inderal is a beta-blocker indicated to treat hypertension, tremors, angina and arrhythmias among other heart or circulatory conditions, but can also be used to reduce the severity and frequency of migraine.

Beta-blocker Tenormin is used for hypertension, arrhythmias and angina treatment, as well as to lower the risk of death after a heart attack.

Meanwhile, Tenoretic uses a combination of beta-blocker and diuretic (chlorthalidone) for the treatment of high blood pressure.

Zestril is designed as an angiotensin-converting enzyme (ACE) inhibitor to treat hypertension, congestive heart failure, diabetic-related conditions and hypertensive renal disease. It may also help improve survival after a heart attack.

Zestoretic is an ACE inhibitor and diuretic (hydrochlorothiazide), used to treat hypertension.

Register as Visitor to CPhI China 2020!

-----------------------------------------------------------------------
Editor's Note:

En-CPhI.CN is a vertical B2B online trade platform serving the pharmaceutical industry,

for any copyright disputes involved in the articles,

please email: Julia.Zhang@imsinoexpo.com to motify or remove the content.